Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689734 | 0.96 | NCF1 (0.41) | NCF1DPP4BPTFHRH3 | |
| SCHEMBL9437303 | 0.91 | NCF1 (0.44) | NCF1DPP4BPTF | |
| SCHEMBL1180398 | 0.87 | NCF1 (0.41) | NCF1DPP4BPTF | |
| SCHEMBL11176985 | 0.83 | MEN1 (0.40) | NCF1DPP4 | |
| SCHEMBL21318624 | 0.83 | DPP4 (0.39) | NCF1DPP4 | |
| SCHEMBL24032980 | 0.83 | CCR2 (0.37) | NCF1 | |
| SCHEMBL5868081 | 0.82 | NCF1 (0.50) | NCF1DPP4HRH3 | |
| SCHEMBL1700154 | 0.82 | NCF1 (0.38) | NCF1BPTFHRH3 | |
| SCHEMBL1699933 | 0.82 | NCF1 (0.38) | NCF1BPTFHRH3 | |
| SCHEMBL1699934 | 0.82 | NCF1 (0.38) | NCF1BPTFHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | NCF1 3093/4885DPP4 2352/4885BPTF 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.